Initiated in 1957 and co-localized and integrated with the Department of Clinical Science (Klinisk Institutt 2), the Broegelmann Research Laboratory (BRL) is lead by Professor Helena Erlandsson Harris, the Broegelmann chair of translation immunology and head of the Immunology and Rheumatology group.
BRL is multinational research environment with group leaders originating throughout Europe and lab members throughout the world. More information about the respective group leaders can be found at this link.
The core financial support for BRL is generously provided by the Broegelmann Foundation, with the fund managed by the The Broegelmann Research Board.
BRL is internationally recognised as one of the leading groups on experimental, clinical and genetic studies of Sjögren's syndrome, see Sjogrens research at BRL (English, Norsk). BRL is closely associated with the Scandinavian Journal of Immunology, Bergen Research School in Inflammation and the Bergen Flow Cytometry Core Facility.
Research performed spans from epidemiology, molecular, genetic and cellular studies to experimental models and studies on clinically well-characterized patient samples. Our ambition is to understand the molecular mechanisms active in different diseases and their subgroups, the underlying risk factors, and triggers. We believe research will pave the way to better, personalized treatment and ultimately to prevention of disease.
To facilitate this endeavour we collaborate closely with clinicians and scientists at Haukeland hospital, within Norway, across Scandinavia and worldwide. We additionally support the development and training of junior researchers in offering ECTS accredited courses and workshops through The Bergen Research School in Inflammation (BRSI).
